Visen Pharmaceuticals has released its unaudited interim results for the six months ended June 30, 2025. The company reported a significant increase in its cash and cash equivalents, which rose to RMB 805.9 million from RMB 203.6 million as of December 31, 2024. However, Visen Pharmaceuticals experienced a rise in its loss for the period, reporting a loss of RMB 118.0 million compared to a loss of RMB 83.5 million for the same period in 2024. Research and development costs increased to RMB 46.6 million from RMB 38.9 million, and administrative expenses rose to RMB 60.0 million from RMB 43.6 million in the previous year. During this period, the company focused on advancing its drug pipeline and aims to expand its franchise in endocrinology within China, including Hong Kong, Macau, and Taiwan. No significant investments or material acquisitions were made during the reporting period, and the capital structure remained unchanged. The company also did not plan any material investments or capital assets as of the announcement date.